The Atlantic

Readers Discuss Extreme Drug Prices—And What to Do About Them

“The public should receive a cut of any drug profits, just as any other investor might.”
Source: Bryan Woolston / Reuters

Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up

Many pharmaceutical companies claim that exorbitant drug costs—some companies charge patients $100,000, $200,000, or even $500,000 a year—are necessary to fund expensive research projects that generate new drugs.

But “invoking high research costs to justify high drug prices,” Ezekiel J. Emanuel wrote last week, “is deceptive.” As even some pharmaceutical executives have acknowledged, he said, “there is no necessary link between a decline in drug prices and a decline in R&D.”


Too many people are focused on driving health costs down. It sounds intuitive, but it misses a bigger opportunity: making health costs most effective.

You’re reading a preview, subscribe to read more.

More from The Atlantic

The Atlantic7 min readAmerican Government
Could South Carolina Change Everything?
For more than four decades, South Carolina has been the decisive contest in the Republican presidential primaries—the state most likely to anoint the GOP’s eventual nominee. On Saturday, South Carolina seems poised to play that role again. Since the
The Atlantic4 min read
Hayao Miyazaki’s Anti-war Fantasia
Once, in a windowless conference room, I got into an argument with a minor Japanese-government official about Hayao Miyazaki. This was in 2017, three years after the director had announced his latest retirement from filmmaking. His final project was
The Atlantic5 min readAmerican Government
What Nikki Haley Is Trying to Prove
This is an edition of The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here. Nikki Haley faces terrible odds in her home state of

Related Books & Audiobooks